Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Completed

• Conditions: Healthy

• Registration Number: NCT00413751
• Lead Sponsor: Walter Reed Army Medical Center

Brief Summary

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Detailed Description

Not available

Study Timeline

• Status Verified: 2006-12
• Study First Submitted: 2006-12-19
• Study First Submitted QC: 2006-12-19
• Last Update Submitted: 2006-12-19
• Study First Posted: 2006-12-20
• Last Update Posted: 2006-12-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria

• Patients not meeting above stated age criteria
• Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
• History of serious ocular, neurological, cardiovascular disease
• History of severe systemic disease
• History of arrhythmias or high blood pressure
• Patients currently taking any type of ocular or systemic medications except multivitamins.
• Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Walter Reed Army Medical Center; 🇺🇸 Washington, District of Columbia, United States